Pfizer - Zyvox, Lyrica

Pfizer - Zyvox, Lyrica

Pfizer Inc allegedly engaged in unfair and deceptive practices in its promotion of Zyvox, including misleading and unsubstantiated superiority claims that broadened the indications for Zyvox, when only approved to treat certain types of infections, including nosocomial pneumonia and other complicated skin infections caused by methicillin-resistant Staphylococcus aureus (MRSA). Moreover, the State alleges that Pfizer Inc engaged in unfair and deceptive practices in promoting Lyrica for off-label uses when only approved to treat certain neuropathic pain. This was a multistate case.